Published: June 2025 | Last updated: May 2026
Daily herpes pills are about to get serious competition. ABI‑5366, a once-weekly oral candidate that may eventually allow once-monthly dosing, posted Phase 1b results across 2025 and early 2026 that surprised even cautious clinicians: a 94% drop in HSV‑2 viral shedding at the weekly dose, and a 76% drop with a single monthly dose (Assembly Biosciences interim Phase 1b release, August 2025). Gilead Sciences exercised its license option in December 2025 and is now steering the program into Phase 2 trials.
If those numbers hold, the way recurrent genital herpes is managed could shift more in the next three years than it has in the last twenty-five. This article walks through what ABI‑5366 actually is, what the trial data show, how it compares to today's daily antivirals like valacyclovir, and what it means in practice for the more than 500 million adults living with HSV‑2 worldwide.
What Is ABI‑5366 and Why Has It Drawn So Much Attention?
ABI‑5366 is an investigational oral antiviral developed by Assembly Biosciences and now licensed to Gilead Sciences. Chemically, it belongs to a class called helicase-primase inhibitors. Functionally, it does something none of the current first-line herpes drugs do: it stays in the body long enough to be dosed once a week, and possibly once a month, instead of every day.
The standout property is its half-life. Phase 1a pharmacokinetic work in 2025 estimated a half-life of roughly 20 days. By comparison, valacyclovir clears the body in hours, which is why daily suppressive therapy with valacyclovir or acyclovir requires consistent every-day dosing to keep blood levels high enough to suppress viral shedding (CDC STI Treatment Guidelines, herpes section).
The reason this matters is partly mechanical and partly behavioral. Mechanically, fewer doses with steadier blood levels can mean more consistent suppression of the viral shedding that drives transmission. Behaviorally, weekly or monthly dosing removes the daily pill-bottle ritual that many people with HSV‑2 describe as the single most stigmatizing part of suppressive therapy.
ABI‑5366 has an estimated half-life of about 20 days. Valacyclovir clears the body in a matter of hours. That single pharmacokinetic difference is the reason weekly or monthly dosing is even on the table for the first time in herpes care.
What the Phase 1b Trials Actually Showed
Phase 1b is where an early-stage drug stops being a chemistry story and starts being a clinical one. Assembly Biosciences enrolled adults with HSV‑2 and a history of recurrent genital herpes, randomized them to ABI‑5366 or placebo, and measured how much of the virus they shed in genital swabs over the trial period. They also tracked how often participants developed genital lesions.
Two readouts have been published so far:
August 2025, weekly dose readout. At 350 mg orally once a week over a 29-day evaluation period, ABI‑5366 produced a 94% reduction in HSV‑2 shedding rate versus placebo (statistically significant), a 98% reduction in high viral load shedding rate, and a 94% reduction in genital lesion rate (Assembly Biosciences press release, August 8, 2025). Those reductions exceeded the company's pre-specified target of 80 to 85% for shedding reduction.
December 2025, monthly dose readout. A proof-of-concept arm tested a single oral monthly dose. Results showed a 76% reduction in HSV‑2 shedding rate, an 81% reduction in high viral load shedding rate, and an 88% reduction in virologically confirmed genital lesion rate (Assembly Biosciences press release, December 8, 2025).
A few important caveats. Phase 1b is small and short, designed to detect signals of activity rather than prove long-term efficacy. The participants in the published readouts were HSV‑2 seropositive adults with recurrent disease; people with first-episode infections, immunocompromised patients, and people with primarily oral HSV‑1 disease were not in scope. And these are interim numbers from a single sponsor's release, not yet peer-reviewed.
Even with those caveats, infectious disease specialists called the Phase 1b shedding reductions notable. Suppressive valacyclovir reduces shedding by roughly 70 to 80% in published trials; the early ABI‑5366 numbers suggest meaningfully greater suppression on a far less frequent dosing schedule.
Will I be able to take a monthly herpes pill soon?
Not in 2026, and probably not in 2027. ABI‑5366 finished Phase 1b in late 2025 with strong activity signals. Gilead is taking it into longer Phase 2 studies in mid-2026. Even on an aggressive timeline, FDA approval typically takes another two to four years after Phase 2 starts. If you have recurrent HSV‑2 today, suppressive valacyclovir or acyclovir remain the standard of care.
How Genital Herpes Is Treated Today
Three antivirals dominate herpes care in 2026, and all three have been around for decades. The CDC's STI treatment guidelines list them with specific dosing for two distinct strategies (CDC STI Treatment Guidelines):
| Drug | Episodic dose (during outbreak) | Suppressive dose (daily) |
|---|---|---|
| Acyclovir | 400 mg orally 3x/day for 5 days | 400 mg orally 2x/day |
| Valacyclovir | 1 g orally 2x/day for 5 days | 500 mg or 1 g orally once daily |
| Famciclovir | 250 mg orally 3x/day for 5 days | 250 mg orally 2x/day |
Why a Weekly or Monthly Pill Could Reshape Daily Life
The clinical advantage is simpler than the chemistry. Suppressive therapy works only when you take it consistently. Adherence research across chronic-disease drugs consistently shows that the more frequent the dose, the lower the real-world adherence. Once-daily medications are taken correctly more often than twice-daily ones; once-weekly options are taken correctly more often than once-daily ones.
For HSV‑2 specifically, a missed dose of valacyclovir opens a window where viral shedding can resume, and shedding (often without a visible lesion) is the primary mechanism by which transmission to a partner happens. A weekly or monthly pill that maintains steady drug exposure could plausibly translate into both fewer outbreaks for the person taking it and lower transmission risk to partners. The Phase 1b data are consistent with that hypothesis but do not yet prove the partner-transmission piece.
There is precedent for this delivery shift in another viral disease. Long-acting injectable HIV regimens like cabotegravir-rilpivirine showed in real-world studies that some people who struggled with daily oral therapy did much better on monthly or every-other-month dosing. ABI‑5366 is an oral pill rather than an injectable, but the underlying adherence argument is the same: a lower dosing burden leads to more consistent real-world use.
How ABI‑5366 Differs From the Acyclovir Class
The older antivirals (acyclovir, valacyclovir, famciclovir) are nucleoside analogs. They get incorporated into the virus's DNA chain as it replicates and stop the chain from extending. They have to be activated by a viral enzyme called thymidine kinase, which is one of the reasons they are very selective for herpes-infected cells. They also have to be present continuously, because they only act on actively replicating virus.
ABI‑5366 targets a different enzyme entirely: a viral protein complex called helicase-primase that unwinds the herpes DNA so it can be copied. Block helicase-primase, and the virus cannot start replication in the first place. This mechanism is independent of thymidine kinase, which matters because the rare strains of HSV that develop resistance to acyclovir do so through thymidine kinase mutations. In other words, ABI‑5366 should remain active against acyclovir-resistant HSV, and lab work to date supports that.
Helicase-primase inhibitors as a class have been studied for years. Pritelivir, a related compound from another sponsor, has gone through clinical trials and is being developed for acyclovir-resistant herpes in immunocompromised patients. ABI‑5366 is the first helicase-primase inhibitor with a half-life long enough to make weekly or monthly dosing feasible.
Reductions in HSV‑2 shedding rate, high viral load shedding rate, and genital lesion rate exceeded the pre-specified target of 80 to 85% for shedding rate reduction at the 350 mg weekly dose, supporting the potential for once-weekly and possibly once-monthly oral dosing regimens.
What's Known About Side Effects and Resistance
Through the Phase 1b interim analyses, ABI‑5366 was reported as well-tolerated at oral doses up to 350 mg weekly. Treatment-emergent adverse events occurred at similar rates in the ABI‑5366 and placebo arms, and most were classified as mild or moderate. One Grade 3 lab abnormality (hypertriglyceridemia) was deemed by investigators to be unrelated to the study drug. As of the December 2025 readout, no serious adverse events had been attributed to the drug.
That is encouraging but provisional. Phase 1b enrolls small numbers of participants for short durations. Side effects that emerge with months or years of use, drug-drug interactions in people taking other medications, and rare events that only appear when thousands of people are exposed are exactly what the larger Phase 2 and Phase 3 studies are designed to find. Until those larger trials are complete, the safety profile should be read as promising rather than settled.
On the resistance question, the helicase-primase mechanism is genuinely novel for HSV. Acyclovir-resistant HSV strains, which are rare in immunocompetent people but a real problem in transplant recipients and people with advanced HIV, would be expected to remain sensitive to ABI‑5366. That is one of the reasons Gilead's interest in the program goes beyond the standard outpatient market.
stdrapidtestkits.com sells the at-home rapid tests referenced in this article. We recommend products based on fit-for-purpose for the reader's concern, not commercial benefit.
The Quiet Mental Load of a Daily Herpes Pill
Clinical trial readouts capture viral shedding rates and lesion counts. They rarely capture the part many people with HSV‑2 mention first when asked: the daily pill itself becomes a daily reminder of a diagnosis they have spent years learning to compartmentalize.
Patient surveys and qualitative research published in journals like Sexually Transmitted Infections and BMC Public Health consistently find that suppressive therapy adherence is shaped by emotional factors as much as by clinical ones. People skip doses on travel days because the bottle is hard to hide. They skip when starting a new relationship because they have not yet had the disclosure conversation. They skip after a long stretch with no outbreaks because the pill starts to feel unnecessary, and the daily ritual feels disproportionate to the visible disease.
A weekly or monthly pill changes the math on this. Taking medication once a month is closer to refilling a prescription than to managing a chronic condition in real time. For people who already use long-acting contraception, the parallel is intuitive: a single decision sustains protection for weeks, instead of a daily check-in.
None of this is a substitute for the existing antivirals, which work and which save outbreaks for millions of people right now. It is, however, the part of the ABI‑5366 story that explains why infectious disease specialists keep using words like "transformative" when discussing it.
How Common Is Genital Herpes, Really?
Two prevalence numbers are worth keeping in mind, because they show how widespread HSV is and how easy it is to underestimate.
The World Health Organization estimates that 520 million people aged 15 to 49 worldwide are living with HSV‑2 infection, which is about 13% of that age group. Most are asymptomatic or have mild, infrequent symptoms; only an estimated 205 million had at least one symptomatic genital herpes episode in 2020.
The picture for HSV‑1 is even larger. The WHO estimates that 3.8 billion people under 50 (about 64% globally) have HSV‑1, primarily as oral herpes acquired in childhood, with a growing share now acquired genitally through oral sex.
In the United States specifically, the CDC's most recent (2018) surveillance data estimated approximately 572,000 new genital herpes infections per year among adults aged 14 to 49 (CDC, About Genital Herpes). Many U.S. adults carry HSV‑2 antibodies without ever being formally diagnosed, because most never develop symptoms recognizable as herpes.
Those numbers are why a more convenient suppressive option matters at a population level. Even modest improvements in adherence and partner-transmission risk could translate to large public health gains across hundreds of millions of people.
520 million adults aged 15 to 49 living with HSV‑2 globally (about 13% of that age group). 205 million had a symptomatic genital herpes episode in 2020. 3.8 billion people under 50 (about 64%) live with HSV‑1, primarily as oral herpes.
Gilead, Phase 2, and the Path to Approval
The commercial story took a sharp turn at the end of 2025. On December 22, 2025, Gilead Sciences exercised an option to exclusively license both ABI‑5366 and a sister candidate, ABI‑1179, from Assembly Biosciences (Gilead Sciences press release, December 22, 2025). Assembly received a $35 million upfront payment with eligibility for up to $330 million in additional milestone payments, plus tiered royalties.
Why does that matter for patients? Two reasons. First, Gilead has the resources, regulatory experience, and global commercial infrastructure to push a complex antiviral through Phase 2, Phase 3, and FDA review. Assembly Bio is a smaller biotech that licensed-out the program at the moment when scale becomes important. Second, no new herpes drug has been approved in the United States or Europe in over 25 years, so the regulatory pathway will need careful design; Gilead has navigated similar pathways for HIV antivirals and is well-suited to the work.
Phase 2 trials are expected to start in mid-2026 and will run substantially longer than the Phase 1b studies. They are designed to confirm efficacy at the planned dosing intervals, refine the dose, study a wider range of participants, and watch for the rarer side effects that small studies miss. Phase 3 typically follows, then FDA review. Even on an optimistic timeline, ABI‑5366 reaching pharmacy shelves in 2028 or 2029 would be considered fast.
Phase 1b: completed late 2025. Gilead license: December 22, 2025. Phase 2 start: mid-2026 expected. Earliest plausible FDA approval: 2028 to 2029 on an optimistic timeline.
What You Can Do Right Now (Before Any of This Ships)
While ABI‑5366 moves through the regulatory pipeline, the practical advice for anyone living with or worried about HSV has not changed much:
- Know your status. A blood antibody test (lab or at-home rapid) can confirm HSV-2 seropositivity 12 weeks or more after a suspected exposure. Antibody tests do not detect active lesions; for visible sores, a clinic-administered swab PCR is the right test.
- If you have recurrent outbreaks, ask about suppressive valacyclovir. It is generic, well-tolerated for most people, and reduces both outbreaks and partner transmission by a meaningful margin.
- Use condoms and disclose to partners. Neither is perfect; together with suppressive therapy they substantially reduce transmission risk.
- Watch the trial pipeline if you are interested. Phase 2 enrollment for ABI-5366 is expected in mid-2026; ClinicalTrials.gov is where you would search for it.
Keeping HSV‑2 in Perspective
HSV‑2 is not, on its own, a medical emergency. It is a manageable chronic infection that affects hundreds of millions of adults globally. The reason a better drug matters is partly clinical (less viral shedding, less transmission, fewer outbreaks) and partly emotional (less daily friction, less stigma). Both reasons are real. Neither is more important than the other.
Frequently asked questions
- Can I get ABI‑5366 prescribed in 2026?
- No. As of May 2026, ABI‑5366 is moving into Phase 2 trials under Gilead Sciences. To check whether a trial enrollment site is near you, search ClinicalTrials.gov for "ABI-5366". Outside of a clinical trial setting, the drug is not currently accessible.
- How is ABI‑5366 different from valacyclovir?
- Valacyclovir is a daily oral pill that works by blocking viral DNA chain extension after activation by a herpes-specific enzyme. ABI‑5366 targets a different enzyme (helicase-primase) and has a much longer half-life, making weekly or potentially monthly dosing feasible. Phase 1b data show greater shedding suppression than typically reported for valacyclovir, on a less frequent dose.
- Will ABI‑5366 cure herpes?
- No. Like all current and near-term herpes treatments, ABI‑5366 is designed to suppress viral activity, not eliminate the latent virus that lives in nerve ganglia. A true cure would need to clear that latent reservoir, which no antiviral in development today does.
- Does ABI‑5366 reduce transmission to partners?
- The Phase 1b data show large reductions in viral shedding, which is the mechanism through which transmission usually occurs. That is a strong signal that transmission would also decrease, but the trials so far have not directly measured partner transmission. Larger Phase 2 and Phase 3 studies will need to confirm that.
- Is the Phase 1b safety data reliable?
- The Phase 1b safety profile through interim analyses is encouraging: no serious adverse events attributed to the drug, side effect rates similar to placebo, and no lab abnormalities of concern. However, Phase 1b enrolls small numbers for short durations. Rare events and long-term effects can only be detected in larger studies.
- What does the Gilead deal mean for patients?
- Gilead exercised an exclusive license for ABI‑5366 and ABI‑1179 in December 2025. Practically, this means a large pharma with deep antiviral experience is now responsible for advancing the program. That makes Phase 2 and Phase 3 development, regulatory filings, and eventual commercial launch more likely to proceed smoothly.
- How can I tell if I have HSV‑2 in the meantime?
- An HSV‑2 type-specific blood antibody test is the standard way to confirm infection in someone without active lesions. Most type-specific assays reliably detect seroconversion 12 to 16 weeks after exposure; testing earlier can produce false negatives. For an active visible sore, a clinic-administered swab PCR is the more accurate test.
- Should I stop taking valacyclovir while I wait for ABI‑5366?
- No. Suppressive valacyclovir or acyclovir remain the standard of care in 2026 and have decades of safety data behind them. There is no clinical reason to discontinue an effective regimen in anticipation of a drug that may take several more years to reach pharmacies.
- Assembly Biosciences. Phase 1b interim results for ABI‑5366, weekly dose readout (August 8, 2025).
- Assembly Biosciences. Phase 1b interim results for ABI‑1179 and ABI‑5366, monthly dose readout (December 8, 2025).
- Gilead Sciences. Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (December 22, 2025).
- U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines, Genital Herpes section (recommended episodic and suppressive antiviral dosing).
- U.S. Centers for Disease Control and Prevention. About Genital Herpes (U.S. incidence figures, prevention, transmission; 2018 surveillance data).
- World Health Organization. Herpes simplex virus fact sheet (global HSV-1 and HSV-2 prevalence estimates).
